Is deep longitudinal profiling available for patients with metastatic colorectal cancer?
Deep longitudinal profiling refers to repeatedly collecting many types of health data from a patient over time, such as tumor genetics, blood tests, gut microbiome, wearable device readings, and lifestyle information. For metastatic colorectal cancer, this approach is being tested in research settings to personalize treatment. A pilot study called High-Definition Oncology (HDO) has shown that collecting this broad, repeated data is feasible in women with metastatic colorectal cancer, among other cancers 4. While not yet standard clinical care, deep profiling is available through clinical trials and specialized research programs.
What the research says
A 2024 pilot study (HDO) enrolled 300 women with metastatic breast, lung, or colorectal cancer to test whether deep longitudinal profiling is feasible 4. The study collects 11 data types repeatedly, including tumor and germline genomics, gut microbiome, blood and stool metabolomics, wearable device data, and digital behavior tracking 4. Early results confirm that harmonized, multi-modal profiling can be done in a multicenter setting, paving the way for truly individualized cancer care 4.
Other research in metastatic colorectal cancer also uses advanced profiling. For example, the CAVE-2 trial used baseline circulating tumor DNA (ctDNA) comprehensive genomic profiling to select patients for anti-EGFR rechallenge therapy 1. Similarly, the SCOPE platform combines patient-derived organoid drug screening with clinical data to predict treatment outcomes 2. These approaches show that molecular profiling is already being integrated into clinical trials for metastatic colorectal cancer.
While deep longitudinal profiling is not yet routine, it represents an evolving area of precision oncology. The HDO study specifically aims to understand how non-genetic factors like microbiome, metabolism, and lifestyle affect treatment response, going beyond standard genomic tests 4. Patients interested in this approach should ask their oncologist about available research studies or clinical trials.
What to ask your doctor
- Are there any clinical trials at this center that involve deep longitudinal profiling for metastatic colorectal cancer?
- What types of data would be collected over time (e.g., blood tests, tumor biopsies, wearable devices)?
- How might participating in a profiling study affect my current treatment plan?
- Are there any costs or risks associated with providing extra samples or data?
- Could the results from profiling help guide future treatment decisions for my cancer?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.